Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Vical Incorporated (NasdaqNM:VICL)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug  6Earnings Announcement
Location
9373 Towne Centre Drive, Suite 100
San Diego, CA 92121
Phone: (858) 646-1100
Fax: (858) 646-1157
Email: aengbring@vical.com
Employees (last reported count): 134
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 14%
·Over the last 6 months:
 · one insider sell; 5,000  shares
  (0.2% of insider shares)
·Institutional: 34% (39% of float)
(139 institutions)
·Net Inst. Buying: 160.0K shares (+2.31%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Vical Incorporated develops biopharmaceutical products based on its patented naked DNA gene transfer technologies for the prevention and treatment of life-threatening diseases. The Company focuses its development on cancer therapies designed to induce an immune response against cancer cells without causing serious side effects. The Company has retained all rights to its internally developed cancer product candidates. Its lead immunotherapy product candidate, Allovectin-7, is in Phase III and Phase II registration trials for patients with advanced metastatic malignant melanoma, an aggressive form of skin cancer, and in a Phase II clinical trial for patients with cancer of the head and neck. Its second immunotherapy product candidate, Leuvectin, is in Phase II clinical trials for patients with advanced metastatic kidney cancer and for high-risk patients with locally confined prostate cancer.
More from Market Guide: Expanded Business Description

Financial Summary
Vical Inc. develops biopharmaceutical products based on their patented naked gene transfer technologies for the prevention and treatment of life-threatening diseases. For the six months ended 6/30/01, total revenues rose 2% to $4.2 million. Net loss before account. change rose 56% to $5.3 million. Revenues reflect higher contract revenues from the Office of Naval Research, the NIH and Pfizer. Higher losses reflect increased personnel related and business development expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

R. Gordon Douglas, Jr., M.D., 67
Chairman
--  --  
Vijay Samant, 48
Pres, CEO, Director
--  --  
Martha Demski, 48
CFO, VP, Sec., Treasurer
$230K$183K
Alan Dow, J.D., Ph.D.
VP, Gen. Counsel
--  --  
Jon Norman, Ph.D., 52
VP of Research
230K335K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:VICLAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$8.531
Recent Price$11.60 
52-Week High
on 5-Sep-2000
$29.875
Beta1.61 
Daily Volume (3-month avg)53.0K
Daily Volume (10-day avg)45.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-58.1%
52-Week Change
relative to S&P500
-43.8%
Share-Related Items
Market Capitalization$232.3M
Shares Outstanding20.0M
Float17.2M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$7.28 
Earnings (ttm)-$0.45 
Earnings (mrq)-$0.16 
Sales (ttm)$0.39 
Cash (mrq)$7.16 
Valuation Ratios
Price/Book (mrq)1.59 
Price/EarningsN/A 
Price/Sales (ttm)30.10 
Income Statements
Sales (ttm)$7.70M
EBITDA (ttm)-$17.1M
Income available to common (ttm)-$8.90M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-5.48%
Return on Equity (ttm)-5.91%
Financial Strength
Current Ratio (mrq)20.48 
Debt/Equity (mrq)0.03 
Total Cash (mrq)$143.3M
Short Interest
As of 8-Aug-2001
Shares Short354.0K
Percent of Float2.1%
Shares Short
(Prior Month)
325.0K
Short Ratio6.56 
Daily Volume54.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.